What is ALS Phase 2-3 Study Arimoclomol?

Category: Others

false

NCT00706147 is a phase II/III randomized, placebo-controlled trial of arimoclomol in SOD1 positive familial amyotrophic lateral sclerosis (ALS). Other Study ID Numbers include arimoclomol in SOD1 fALS.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 3

Commonly reported side effects and conditions associated with ALS Phase 2-3 Study Arimoclomol

Side effect Patients Percentage

Why patients stopped taking ALS Phase 2-3 Study Arimoclomol

Multiple reasons could be selected

Reason Patients Percentage
Course of treatment ended 3
Other 1
Personal research 1
See all 5 patients who've stopped using ALS Phase 2-3 Study Arimoclomol

Duration

Stopped using ALS Phase 2-3 Study Arimoclomol

Duration Patients Percentage
1 - 6 months 2
6 months - 1 year 1
1 - 2 years 2
Adherence
Adherence Evaluations Percentage
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 2
Not at all hard to take 1
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 2
Last updated:
There are no evaluations for ALS Phase 2-3 Study Arimoclomol.